Is Trident Texofab overvalued or undervalued?
As of August 29, 2025, Trident Texofab is considered overvalued with a valuation grade of expensive, reflected in its high PE ratio of 133.86, EV to EBITDA of 76.80, and PEG ratio of 6.36, especially when compared to peers like PTC India at 8.35 and Lloyds Enterprises at 38.87, despite a remarkable 1-year return of 456.44%.
As of 29 August 2025, the valuation grade for Trident Texofab has moved from very expensive to expensive. The company is currently considered overvalued based on its high valuation ratios. Notable ratios include a PE ratio of 133.86, an EV to EBITDA of 76.80, and a PEG ratio of 6.36, all of which indicate a premium valuation compared to typical industry standards.In comparison to peers, Trident Texofab's PE ratio significantly exceeds that of PTC India, which is very attractive at 8.35, and Lloyds Enterprises, which is very expensive at 38.87. This stark contrast highlights the overvaluation of Trident Texofab. Additionally, the company's recent stock performance has been impressive, with a 1-year return of 456.44%, far outpacing the Sensex's decline of 2.83%, although this does not mitigate the concerns regarding its current valuation.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
